Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

16.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
16.4K
Antibody Actions01:26

Antibody Actions

1.7K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.7K
Immunoprecipitation01:20

Immunoprecipitation

6.3K
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated surveillance for lymphatic filariasis and other infectious diseases with a nationwide non-communicable disease STEPwise survey in the small Pacific Island Nation of Niue, 2025.

Scientific reports·2026
Same author

Comparison of an integrated versus stand-alone approach to post-validation surveillance for lymphatic filariasis in Niue: a micro-costing study, 2025.

Journal of global health·2026
Same author

Accountability for care through undoing racism and equity for moms: a study protocol for a cluster randomized trial of data accountability and community-based doula interventions in prenatal practices.

Trials·2026
Same author

Redesigning a Serious Illness Conversation Guide: A Mixed-Methods Community-Engaged Revision Process.

Journal of pain and symptom management·2026
Same author

The association between interoception and psychopathic traits.

Frontiers in psychology·2026
Same author

The Massachusetts Model: A Roadmap for Advancing Serious Illness Care in Nursing Education.

Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association·2025

Related Experiment Video

Updated: Nov 7, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.9K

Patenting antibody combination therapies.

Li Feng1, Lin Chen1, Amanda Murphy1

  • 1Finnegan, Henderson, Farabow, Garrett & Dunner LLP., 901 New York Avenue, NW, Washington, DC 20001-4413, USA.

Antibody Therapeutics
|April 30, 2021
PubMed
Summary

Antibody combination therapies face intellectual property hurdles. Demonstrating unexpected results and a clear link to claims can help secure patents for these innovative treatments.

Keywords:
ADCCombination therapyInventionObviousnessPatent

More Related Videos

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations
09:07

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Published on: August 22, 2019

11.1K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.6K

Related Experiment Videos

Last Updated: Nov 7, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.9K
Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations
09:07

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Published on: August 22, 2019

11.1K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.6K

Area of Science:

  • Biotechnology
  • Pharmaceutical Sciences
  • Intellectual Property Law

Background:

  • Antibody combination therapies are gaining significant attention in drug development.
  • These therapies present unique challenges in securing adequate intellectual property protection.
  • Existing patents may be difficult to obtain due to obviousness concerns regarding known components.

Purpose of the Study:

  • To explore the intellectual property challenges associated with antibody combination therapies.
  • To identify strategies for obtaining robust patent protection for these inventions.
  • To analyze the criteria patent examiners use to assess the patentability of antibody combinations.

Main Methods:

  • Analysis of patent examination guidelines and case law related to pharmaceutical combinations.
  • Review of strategies for demonstrating non-obviousness in patent claims.
  • Examination of how unexpected results and objective evidence impact patentability.

Main Results:

  • Patent examiners may consider antibody combinations obvious if individual components are known and studied.
  • Non-obviousness can be established if there was no motivation to combine or reasonable expectation of success.
  • Unexpected superior results can provide objective evidence of non-obviousness for antibody combinations.

Conclusions:

  • Securing patents for antibody combination therapies requires careful strategic claim drafting.
  • Demonstrating a lack of motivation to combine or unexpected synergistic effects is crucial.
  • Establishing a nexus between superior results and the claimed combination strengthens patentability.